国际站：Teclistamab

CAS：2119595-80-9

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Teclistamab 是一种人源化的 BCMA 和 CD3 双特异性抗体，可识别靶细胞上的 BCMA 和 T 细胞上的 CD3，诱导 T 细胞介导的细胞毒性，导致 T 细胞的活化和随后的靶细胞裂解。Teclistamab 可用于多发性骨髓瘤等相关疾病研究。

体外：Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC50 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM[1]。 Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 +人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NSG mice infected with H929 cell lines[1] Dosage: 0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg) Administration: i.v., on days 0, 3, 5, 7, and 10 Result: Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg. Clinical Trial

参考文献：

[1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549.